The latest -Biomarker Technology Platforms for Cancer Diagnoses and Therapies -Report By Aarkstore

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 23, 2012 -- Biomarker Technology Platforms for Cancer Diagnoses and Therapies

http://www.emarketreports.com/reports/Biomarker-Technology-Platforms-for-Cancer-Diagnoses-and-Therapies-1299.html

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this TriMark Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.

Table of Contents :

1. Overview

1.1 Statement of Report

1.2 About This Report

1.3 Scope of the Report

1.4 Objectives

1.5 Methodology

1.6 Executive Summary

2. Introduction to Cancer Biology and the Diagnostic Industry

2.1 Biomarkers

2.1.1 The Biomarker Market Drivers

2.1.1.1 The Sector

2.1.1.2 The Critical Path Opportunities

2.1.1.3 The Capital Markets

2.2 Cancer Detection and Treatment with Biomarkers

2.2.1 The Problem

2.3 Cancer: The Disease

2.3.1 Metastasis

2.3.2 Demographics and Statistics of Cancer

INDEX OF FIGURES

Figure 3.1: Potential Market for Cancer Biomarkers, 2006

Figure 3.2: Segmentation of the Cancer biomarkers Marketplace Based Upon Commercial Offerings—Products and Services

Figure 3.3: Geographical Distribution of Cancer Tumor Diagnostic Testing

Figure 3.4: Cancer Biomarkers Research Market, 2006-2011

Figure 3.5: Breast Cancer Biomarker Market Potential, 2005

Figure 3.6: Challenges in the Study or Utilization of Proteomic Cancer Biomarkers

Figure 3.7: Challenges in the Study or Utilization of Companion Diagnostic Cancer Biomarkers


INDEX OF TABLES

Table 2.1: Cancer Biomarkers at the Nexus Point

Table 2.2: Drug Development by Type of Cancer

Table 2.3: Organ Specific Medicines in Development for Cancer, 2006

Table 2.4: Estimates for the Leading Sites of New Cancer Cases and Deaths in the U.S. by Sex, 2007

Table 2.5: Estimated Worldwide Number of New Cancer Cases and Deaths by Type of Cancer

Table 2.6: Estimated Number of New Cancer Cases and Deaths by Region

Biomarkers     cancer     diagnostic testing